Evidence map›Paper›PMID 40606773›Full record

ArticleCanadian journal of kidney health and disease2025

Program Report-Transplant Manitoba Adult Kidney Program Cutting Costs, Not Corners: Value of Quality Improvement Initiatives.

Christie Rampersad, Aaron Trachtenberg, James Shaw, Nancy Dodd, Krista Maxwell, Martin Karpinski, Chris Wiebe, Peter Nickerson, Julie Ho

Abstract read
In one paragraph

Article in Canadian journal of kidney health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Christie RampersadAjmera Transplant Centre, Toronto General Hospital, University Health Network, ON, Canada.
Aaron TrachtenbergAdult Kidney Transplant Program, Transplant Manitoba, Winnipeg, Canada.ORCID https://orcid.org/0000-0001-8940-5458
James ShawAdult Kidney Transplant Program, Transplant Manitoba, Winnipeg, Canada.
Nancy DoddAdult Kidney Transplant Program, Transplant Manitoba, Winnipeg, Canada.
Krista MaxwellAdult Kidney Transplant Program, Transplant Manitoba, Winnipeg, Canada.
Martin KarpinskiAdult Kidney Transplant Program, Transplant Manitoba, Winnipeg, Canada.
Chris WiebeAdult Kidney Transplant Program, Transplant Manitoba, Winnipeg, Canada.
Peter NickersonAdult Kidney Transplant Program, Transplant Manitoba, Winnipeg, Canada.
Julie HoAdult Kidney Transplant Program, Transplant Manitoba, Winnipeg, Canada.ORCID https://orcid.org/0000-0002-8342-9093

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Provision of high-quality, evidence-based patient care that is sustainable for our universal health system is a core Canadian Medical Education Directions for Specialists (CanMEDs) expectation. The Transplant Manitoba Adult Kidney Program (TMAKP) embraced this responsibility by addressing inefficiencies in its practices through multipronged quality improvement (QI) strategies, including reducing unnecessary interventions, implementing innovative strategies, and aligning clinical practices with emerging evidence. Using seamlessly embedded continuous QI and clinical research with a learning health system, the program achieved substantial cost savings and increased opportunities for deceased donor kidney transplantation. The purpose of this analysis is to measure the cost savings associated with these QI initiatives. Sources of information: Transplant Manitoba Adult Kidney Program database and quality metrics, Manitoba Health Physician's Manual (April 1, 2024), PubMed. Methods: To quantify the potential cost savings, we employed a 3-pronged approach. For reduced testing, a cost-counting exercise was conducted using historical transplant activity (831 prevalent and 83 incident patients) to project number of tests avoided and direct costs per test. Second, cost savings for generic mycophenolic acid was presented as ratios of generic to brand name drug costs, and projected cost savings for prevalent patients receiving average dosing. Third, for increased kidney utilization, cost savings per kidney transplant were derived from published studies and extrapolated using predicted additional transplants. Net health care system savings across payers were assessed at a 1-year time horizon. Key Findings: The TMAKP reduced unnecessary testing, adopted generic medications, and implemented innovative strategies, achieving $2,530,026 in projected annual 1-year cost savings. These QI initiative savings augment the overall cost-effectiveness of kidney transplantation compared with dialysis. Implementing evidence-based protocols using personalized risk-stratified approaches to viral monitoring and novel donor-specific antibody surveillance strategies aligned testing with clinical risk while minimizing patient burden, highlighting the benefits of seamlessly integrating research with learning health systems. Programs for hepatitis C-viremic donor kidneys and age-targeted allocation increased transplant opportunities and optimized deceased donor organ use. Manitoba's initiatives demonstrate the importance of validation, stakeholder engagement, and iterative adaptation in driving sustainable improvements in transplantation care. Critically, this requires the foresight of health care administrative systems to invest in effective and ongoing QI and embed research with clinical practice, to improve patient and health system outcomes. Limitations: This analysis is limited by reliance on projected cost savings, which require validation through real-world audits to confirm impact. In addition, some valuable QI efforts, while improving patient outcomes, may increase costs, highlighting the need for balanced perspectives in assessing stewardship initiatives. Finally, this analysis is limited to projected cost savings and does not evaluate clinical outcomes, process adherence, or implementation effectiveness. Implications: This experience highlights the potential for QI initiatives to optimize care and resource utilization within Canada's publicly funded health system. These efforts reduced unnecessary testing, minimized patient burden, and expanded transplant opportunities, illustrating how stewardship can balance fiscal responsibility with high-quality state-of-the-art patient care. By implementing evidence-based protocols, TMAKP achieved an additional $2,530,026 in projected cost savings at 1 year. Future annual cost savings will continue rising in a growing prevalent kidney transplant population in Manitoba. These savings can be reallocated to other critical health care services, expanding access and improving outcomes for patients beyond transplantation.

Indexed as

choosing wiselycost-effectivenesskidney transplantationlearning health systemsquality improvement

Identifiers

PMID40606773
PMCPMC12217574

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.